BGOG-ov-43

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • AZ Maria Middelares, Gent
  • Imelda Ziekenhuis, Bonheiden
  • Grand Hôpital de Charleroi, Charleroi
  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • Jessa Ziekenhuis, Hasselt
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Antwerpen, Antwerpen
  • CHU UCL St-Luc, Bruxelles